91 related articles for article (PubMed ID: 2178354)
1. Molecular biology and the control of viral vaccines.
Minor PD; Macadam A; Cammack N; Dunn G; Almond JW
FEMS Microbiol Immunol; 1990 Nov; 2(4):207-13. PubMed ID: 2178354
[TBL] [Abstract][Full Text] [Related]
2. [Isolation of recombinant vaccine strains of poliovirus from patients with poliomyelitis].
Kutitova OK; Lipskaia GIu; Maslova SV; Agol VI
Mol Gen Mikrobiol Virusol; 1989 Nov; (11):14-20. PubMed ID: 2560812
[TBL] [Abstract][Full Text] [Related]
3. Live-attenuated strains of improved genetic stability.
Macadam AJ; Ferguson G; Stone DM; Meredith J; Almond JW; Minor PD
Dev Biol (Basel); 2001; 105():179-87. PubMed ID: 11763326
[TBL] [Abstract][Full Text] [Related]
4. Rapid and accurate identification of poliovirus strains used for vaccine production.
Nijst OE; Mouthaan JJ; Mekkes DR; Jusic E; van der Avoort HG; Metz B
J Virol Methods; 2013 Apr; 189(1):189-95. PubMed ID: 23434540
[TBL] [Abstract][Full Text] [Related]
5. Development of candidates for new type 2 and type 3 oral poliovirus vaccines.
Kohara M; Abe S; Yoshioka I; Nomoto A
Dev Biol Stand; 1993; 78():141-8. PubMed ID: 8388824
[TBL] [Abstract][Full Text] [Related]
6. Attenuation and reversion of the Sabin vaccine strains of poliovirus.
Minor PD
Dev Biol Stand; 1993; 78():17-26. PubMed ID: 8388828
[TBL] [Abstract][Full Text] [Related]
7. Development of a multiplex RT-PCR assay for the identification of recombination types at different genomic regions of vaccine-derived polioviruses.
Dimitriou TG; Kyriakopoulou Z; Tsakogiannis D; Fikatas A; Gartzonika C; Levidiotou-Stefanou S; Markoulatos P
Virus Genes; 2016 Aug; 52(4):453-62. PubMed ID: 27098645
[TBL] [Abstract][Full Text] [Related]
8. Mutations in Sabin 2 strain of poliovirus and stability of attenuation phenotype.
Rezapkin GV; Fan L; Asher DM; Fibi MR; Dragunsky EM; Chumakov KM
Virology; 1999 May; 258(1):152-60. PubMed ID: 10329577
[TBL] [Abstract][Full Text] [Related]
9. Risks associated with the use of live-attenuated vaccine poliovirus strains and the strategies for control and eradication of paralytic poliomyelitis.
Pliaka V; Kyriakopoulou Z; Markoulatos P
Expert Rev Vaccines; 2012 May; 11(5):609-28. PubMed ID: 22827246
[TBL] [Abstract][Full Text] [Related]
10. Harnessing endogenous miRNAs to control virus tissue tropism as a strategy for developing attenuated virus vaccines.
Barnes D; Kunitomi M; Vignuzzi M; Saksela K; Andino R
Cell Host Microbe; 2008 Sep; 4(3):239-48. PubMed ID: 18779050
[TBL] [Abstract][Full Text] [Related]
11. Sabin Vaccine Reversion in the Field: a Comprehensive Analysis of Sabin-Like Poliovirus Isolates in Nigeria.
Famulare M; Chang S; Iber J; Zhao K; Adeniji JA; Bukbuk D; Baba M; Behrend M; Burns CC; Oberste MS
J Virol; 2016 Jan; 90(1):317-31. PubMed ID: 26468545
[TBL] [Abstract][Full Text] [Related]
12. A Cluster of Paralytic Poliomyelitis Cases Due to Transmission of Slightly Diverged Sabin 2 Vaccine Poliovirus.
Korotkova EA; Gmyl AP; Yakovenko ML; Ivanova OE; Eremeeva TP; Kozlovskaya LI; Shakaryan AK; Lipskaya GY; Parshina IL; Loginovskikh NV; Morozova NS; Agol VI
J Virol; 2016 Jul; 90(13):5978-88. PubMed ID: 27099315
[TBL] [Abstract][Full Text] [Related]
13. Significance of a newly identified attenuating mutation in Sabin 3 oral poliovirus vaccine.
Mento SJ; Weeks-Levy C; Tatem JM; Gorgacz EJ; Waterfield WF
Dev Biol Stand; 1993; 78():93-9; discussion 99-100. PubMed ID: 8388835
[TBL] [Abstract][Full Text] [Related]
14. Antigenic and molecular evolution of the vaccine strain of type 3 poliovirus during the period of excretion by a primary vaccinee.
Minor PD; John A; Ferguson M; Icenogle JP
J Gen Virol; 1986 Apr; 67 ( Pt 4)():693-706. PubMed ID: 2420925
[TBL] [Abstract][Full Text] [Related]
15. Recombinant polioviruses as candidate strains of oral poliovaccines.
Nomoto A
Dev Biol Stand; 1995; 84():123-7. PubMed ID: 7796944
[No Abstract] [Full Text] [Related]
16. Genetic stability and instability of the cis-acting control element of the 5' untranslated region of the poliovirus RNA.
Agol VI
Dev Biol Stand; 1993; 78():11-6. PubMed ID: 8388821
[TBL] [Abstract][Full Text] [Related]
17. WHO recommendation on potential use of new poliomyelitis vaccines.
Ghendon Y
Dev Biol Stand; 1993; 78():133-7; discussion 138-9. PubMed ID: 8388823
[TBL] [Abstract][Full Text] [Related]
18. Infectious cDNA, cell receptors and transgenic mice in the study of Sabin's poliovirus vaccines.
Racaniello VR
Biologicals; 1993 Dec; 21(4):365-9. PubMed ID: 8024752
[TBL] [Abstract][Full Text] [Related]
19. Molecular characterization of poliovirus isolates from children who contracted vaccine-associated paralytic poliomyelitis (VAPP) following administration of monovalent type 3 oral poliovirus vaccine in the 1960s in Hungary.
Kapusinszky B; Molnár Z; Szomor KN; Berencsi G
FEMS Immunol Med Microbiol; 2010 Mar; 58(2):211-7. PubMed ID: 19863665
[TBL] [Abstract][Full Text] [Related]
20. Type 2 poliovirus recombinants isolated from vaccine-associated cases and from healthy contacts in Brazil.
Friedrich F; Da-Silva EF; Schatzmayr HG
Acta Virol; 1996 Feb; 40(1):27-33. PubMed ID: 8886095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
